Common Contracts
2 similar Clinical Trial Agreement contracts
ContractClinical Trial Agreement • October 5th, 2022
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-590-6154 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-590-6154 This Clinical Trial Agreement (“Agreement”) is entered by and among University hospital Ostrava, a hospital with an address at 17. listopadu 1790/5, Ostrava - Poruba, 708 52, Czech Republic, company identification number: 00669806, tax identification number: CZ00669806 (the “Institution”), MUDr. Petr Vávra, Ph.D., Deputy Director for Science, Research and Education is authorized to act and sign in matters of this contract. Dr. Zdenek Koristek the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at xxxxxx (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-590-6154, “A Phase 3, Randomized, Double- Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Aza
Ev. č. FNO: 017/OVZ/21/062-PClinical Trial Agreement • February 10th, 2022
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-558-5915 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-558-5915 This Clinical Trial Agreement (“Agreement”) is entered by and among University hospital Ostrava, a hospital with an address at 17. listopadu 1790/5, Ostrava - Poruba, 708 52, Czech Republic, company identification number: 00669806, tax identification number: CZ00669806 (the “Institution”), MUDr. Petr Vávra, Ph.D., Deputy Director for Science, Research and Education is authorized to act and sign in matters of this contract. prof. MUDr. Roman Hajek CSc., the investigator for the Trial (the “Investigator”) working at Hematooncology Department, University hospital Ostrava, 17. listopadu 1790/5, 708 52 Ostrava- Poruba, Czech Republic and Gilead Sciences, Inc., a Delaware corporation with headquarters located at xxxxxxxx (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-558-5915, “A Phase 2 Multi-Arm Study
